[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528009":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":51,"collaborators":20,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":20,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PT\u002FFLU+CY","EXPERIMENTAL","The group consisted of fludarabine (40mg\u002Fm2, day-5 to day-3 and day+3, day+4), busulfan (100mg\u002Fm2, day-6 to day-3), haplo-PBSC (day0), cyclophosphamide (50mg\u002Fkg, day+3, day+4) , and UCB (day+6)",[13],"Procedure: applying of FLU+CY post-HSCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","applying of FLU+CY post-HSCT","The conditioning regimen (PT-Cy\u002FFlu group) consisted of fludarabine (40mg\u002Fm2, d-5 to d-3 and d+3, d+4), busulfan (100mg\u002Fm2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg\u002Fkg, d+3, d+4) and UCB (d+6).",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Xiaoqin Feng, MD","Department of Pediatrics, Nanfang Hospital, Southern Medical University","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Yongsheng Ruan, MD","CONTACT","02062787966","vimmer@smu.edu.cn",{"name":23,"role":29,"phone":33,"phoneExt":20,"email":34},"+861382222","fxq126126@126.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Nanfang Hospital","RECRUITING","Guangzhou","Guangdong","510515","China",{"type":44,"coordinates":45},"Point",[46,47],113.25,23.11667,{"lat":47,"lon":46},[50],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100528009",false,"NCT06155188","Post-transplant PT\u002FFLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia","A Novel Post-transplant Regimen of PT\u002FFLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial","Inclusion Criteria:\n\n* children acute leukemia\n\nExclusion Criteria:\n\n* MODS","ALL","1 Month","18 Years",{"count":63,"type":64},60,"ESTIMATED","INTERVENTIONAL",[67],"NA","To determine if the novel regimen of PT\u002FFLU+CY promotes cord blood engraftment in children's leukemia HSCT cohort",[70,71,72],"Leukemia","Stem Cell Transplant","Cord Blood","2023-11-23",{"date":75,"type":76},"2023-12-04","ACTUAL",{"date":78,"type":76},"2019-09-29",{"date":80,"type":64},"2026-12",{"name":5,"class":6},1]